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SUMMARY
Chuvash polycythemia (CP) is a rare congenital form of polycythemia caused by homozygous
R200W and H191D mutations in the von Hippel-Lindau (VHL) gene whose gene product is the
principal negative regulator of hypoxia-inducible factor. However, the molecular mechanisms
underlying some of the hallmark features of CP such as hypersensitivity to erythropoietin are
unclear. Here, we show that VHL directly binds suppressor of cytokine signalling 1 (SOCS1) to
form a heterodimeric E3 ligase that targets phosphorylated (p)JAK2 for ubiquitin-mediated
destruction. In contrast, CP-associated VHL mutants have altered affinity for SOCS1 and fail to
engage and degrade pJAK2. Systemic administration of a highly selective JAK2 inhibitor,
TG101209, reverses the disease phenotype in vhlR200W/R200W knock-in mice, a model that
faithfully recapitulates human CP. These results reveal VHL as a SOCS1-cooperative negative
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regulator of JAK2 and provide compelling biochemical and preclinical evidence for JAK2-
targeted therapy in CP patients.
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INTRODUCTION
von Hippel-Lindau (VHL) protein is the substrate-conferring component of an E3 ubiquitin
ligase ECV (Elongins BC/Cul2/VHL) that polyubiquitylates α subunits of hypoxia-inducible
factor (HIF), a master transcription factor that governs adaptive cellular responses to
hypoxia, for oxygen-dependent destruction 1–4. Under hypoxia, HIFα escapes ECV-
mediated destruction and partners with HIFβ to form an active transcription factor that
engages hypoxia-responsive elements (HRE) in the promoters/enhancers of numerous
hypoxia-inducible genes including glucose transporter-1 (GLUT-1), vascular endothelial
growth factor (VEGF) and erythropoietin (EPO) to promote anaerobic metabolism,
angiogenesis and erythropoiesis, respectively5.
Inheritance of a mutated VHL gene causes VHL disease, an autosomal dominant cancer
syndrome characterized by the development of cerebellar and rentinal haemangioblastoma,
phaeochromocytoma and clear-cell renal cell carcinoma (CCRCC)5. Although the incidence
of VHL disease is rare at 1 in 36,000 individuals, biallelic inactivation of VHL is frequently
associated with sporadic haemangioblastoma and CCRCC 6. Most tumour-associated VHL
mutants have been shown or are predicted to compromise the ability of VHL to either bind
prolyl-hydroxylated HIFα or form a proper ECV complex7,8, and additional lines of
investigation have demonstrated the critical oncogenic role of HIFα in CCRCC 9–12.
Recently, Ang et al. identified a specific homozygous mutation 598C→T (R200W) within
VHL that causes congenital autosomal recessive Chuvash polycythemia (CP) endemic to the
Chuvash Autonomous Republic of the Russian Federation 13. Subsequently, R200W and
additional mutations (e.g., H191D) have been identified in a significant proportion of
congenital polycythemia patients in diverse ethnic backgrounds without gender
bias 14,15–16,17, suggesting that a defect in the ability of CP-VHL to maintain proper oxygen
homeostasis to be the principal mechanism underlying CP 13,16,18,19. Curiously however,
unlike classical VHL disease, CP is not associated with an increased risk of cancer despite a
common defect in the HIF pathway, which illustrates a current inability to distinguish
biochemical features between CP- and tumour-associated VHL mutants.
Polycythemia is a condition characterized by a net increase in the total number of red blood
cells (RBCs) resulting in an elevated haematocrit (Hct), and is generally categorised as
primary or secondary. Primary polycythemia, often called polycythemia vera (PV), is
defined as excessive erythrocytosis arising from an intrinsic defect in erythroid progenitors
rendering them hypersensitive to or independent of EPO stimulation 20. Secondary
polycythemia is defined as excessive erythrocytosis arising from increased production of
EPO 20, most often secondary to conditions of chronic hypoxia such as individuals with
chronic obstructive pulmonary disease or smokers but also as paraneoplastic syndromes
associated with certain malignancies including renal cell and hepatocellular carcinoma.
Secondary polycythemia can also originate through mutations in PHD2 and HIF2α that
ultimately promote EPO production 21–23, recapitulated in mice with constitutive expression
of HIF2α 16,24.
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JAK2 mutations, predominated by V617F that encodes constitutively active JAK2, have
recently been identified in the vast majority of PV patients25–29. JAK2 binds most
prominently to Signal Transducers and Activator of Transcription (STAT5) protein, which,
upon phosphorylation by JAK2, dimerize and translocate to the nucleus to regulate
expression of genes that control proliferation, differentiation and survival of haematopoietic
cells 30. STAT5 also triggers a negative feedback mechanism by transactivating the
expression of SOCS family members, which bind and inhibit activated JAKs31. Notably,
SOCS1 directly binds and targets phosphorylated JAK2 for ubiquitin-mediated degradation
via E3 ubiquitin ligase ECS (Elongins BC/Cul2 or 5/SOCS1) 32,33. In addition, colony-
forming units-erythroid (CFU-E) cells from the fetal livers of SOCS1−/− mice were shown
to be hyper-responsive to EPO 34. Moreover, JAK2(V617F) mutation induced PV
phenotype in mouse bone marrow transplantation assays, and the introduction of
JAK2(V617F) into cytokine-dependent cell lines promoted cytokine- independent
signalling 35–38. Regardless of JAK2(V617F) mutation status, however, high STAT5
phosphorylation is detected in bone marrow biopsies of PV patients39. These lines of
evidence suggest that constitutive activation of JAK2-STAT5 signalling is a major causative
determinant of PV, and that JAK2(V617F)-negative PV patients might harbour yet-
identified mutations in genes encoding proteins in the JAK2-STAT5 pathway.
Most CP patients and vhlR200W/R200W (VhlR/R) mice that faithfully recapitulate the human
CP condition have elevated EPO levels, a hallmark feature of secondary polycythemia, due
to the diminished capacity of CP-VHL(R200W) to bind HIFα 13, resulting in increased HIF-
mediated transactivation of EPO. Intriguingly, there are also data from both mouse and
human studies that suggest CP-associated VHL mutations mediate primary polycythemia. In
particular, erythroid precursors from both CP patients and VHLR/R mice exhibit an intrinsic
hypersensitivity to EPO displayed by burst forming units-erythroid (BFU-E) cells 13,18.
However, the molecular mechanism underlying this and other primary polycythemic
features of CP is unknown.
RESULTS
CP-VHL mutants have reduced capacity to form ECV
A subset of tumour-associated VHL mutants is unable to form a proper ECV complex. We
first asked whether CP-VHL mutants were similarly defective in binding to ECV
components, and observed that CP-VHL (R200W and H191D; exhibits slightly faster
migration under reducing conditions) mutants have diminished association with Elongins
BC and Cul2 (Fig. 1a, b and Supplementary Fig. 1a). The tumour-associated VHL(C162F)
mutant, which is known to be defective in forming an ECV complex40, served as control.
Thus, in addition to the previously reported defect in HIFα binding, CP-VHL mutants are
compromised in ECV assembly, which also likely contributes to HIFα stabilization.
All tumour-associated VHL mutants tested-to-date have invariably shown a failure in
binding to fibronectin (FN) and a concomitant defect in formation of FN fibrillar array in the
extracellular space41. However, CP-VHL mutants showed robust extracellular FN matrix
with distinct fibrillar array similar to wild-type VHL (Supplementary Fig. 1b and data not
shown). Thus, VHL(R200W) and VHL(H191D) are the first naturally occurring disease-
associated VHL mutants exhibiting proper FN matrix deposition, which is consistent with
the absence of cancer predisposition in individuals with CP.
VHL binds to JAK2 in a proteasome- and EPO-dependent manner
In addition to reduced Cul2 binding, 35S-metabolic labeling of 786-O (VHL−/−) cells stably
expressing VHL(R200W or H191D) revealed an associated protein of 120kDa in the
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absence of proteasome inhibitor (Fig. 1b). JAK2 is approximately 120KDa and through its
actions on STAT5 signalling is known to be a critical mediator of proliferation and survival
of erythroid progenitor cells. Thus, we asked whether VHL interacts with JAK2. HA-
VHL(WT) co-precipitated T7-JAK2 when co-expressed in HEK293 cells in a proteasome-
dependent manner (Fig. 1c). Interestingly, HA-VHL(R200W and H191D) showed increased
association with (p)JAK2 in comparison to HA-VHL(WT) in the absence of proteasome
inhibitor (Fig. 1d). These results identify JAK2 as a proteasome-sensitive VHL-binding
substrate and suggest that CP-VHL mutants have a diminished capacity to promote
proteasome-dependent degradation of JAK2.
Notably, total level of JAK2 remained relatively unchanged upon HA-VHL(WT) expression
(Fig. 1c and d, lower panels). We therefore sought to determine whether VHL bound to and
degraded pJAK2. Introduction of HA-VHL(WT) in HEK293 cells resulted in a dramatic loss
of pJAK2, while the total JAK2 expression remained relatively unchanged (Fig. 2a). In
addition, the mouse haematopoietic cell line expressing EPO receptor (BaF3-EPOR) was
stably infected with retrovirus encoding HA-human VHL to generate near-endogenous
expression level of HA-VHL (Fig. 2b, lane 4, compare endogenous mouse (m)VHL level to
slower migrating HA-human VHL). HA-VHL in BaF3-EPOR cells bound to endogenous
JAK2 preferentially upon EPO stimulation in the presence of MG132, suggesting that the
proteasome-sensitive substrate of VHL is pJAK2 (Fig. 2b).
VHL promotes ubiquitin-mediated degradation of pJAK2
We next asked whether VHL promotes ubiquitin-mediated degradation of activated JAK2,
which is defined by Y1007/1008 phosphorylation 42. HEK293 cells were co-transfected with
plasmids encoding T7-JAK2 and EPOR and stimulated with EPO for 15 min to generate
robust levels of pJAK2 (Fig. 2c, left panel). The whole cell extract was then
immunoprecipitated with antibodies specific to T7 and the enriched T7-pJAK2 was then
subjected to an in vitro ubiquitylation reaction using S100 extracts devoid of or reconstituted
with VHL(WT) (Fig. 2c, right panel). While the total JAK2 expression was unaffected, the
level of pJAK2 expression decreased dramatically in the presence of VHL(WT), which was
accompanied by the appearance of pJAK2 polyubiquitylation (Fig. 2c, lane 4). The low level
of VHL-dependent ubiquitylation observed in the absence of EPO is likely due to limited
spontaneous JAK2 autophosphorylation, which is commonly observed upon ectopic JAK2
expression (Fig. 2c, right panel, lane 3). In addition, retrovirus driven shRNA-mediated
knockdown of endogenous mVHL in BaF3-EPOR cells accentuated pJAK2 expression and
downstream STAT5-responsive gene expression such as PIM1 and CISH upon EPO
treatment in comparison to BaF3-EPOR cells infected with retrovirus encoding non-
targeting scrambled shRNA (Fig. 2d). VHL knockdown had negligible effect on SOCS1
expression, making non-specific changes in SOCS1 expression an unlikely explanation for
the observed pJAK2 induction (Fig. 2d, lanes 1 and 2). These results suggest that VHL
preferentially engages JAK2 upon EPOR activation to trigger ubiquitin-mediated down-
regulation of pJAK2.
VHL patients rarely develop polycythemia despite harbouring VHL mutations that
compromise HIFα degradation 18. If deregulation of pJAK2 is involved in VHL-associated
polycythemia, then tumour-associated VHL mutants incapable of binding or ubiquitylating
HIFα are predicted to retain the ability to promote ubiquitin-mediated destruction of pJAK2.
Consistent with our prediction, expression of a panel of tumour-associated VHL mutants,
with the exception of F119S and L128F (discussed below), resulted in markedly lower
pJAK2 expression in the absence of MG132 similar to wild-type VHL (Fig. 2e). In addition,
a panel of tumour-associated VHL mutants retained binding to JAK2 in the presence of
MG132 (Supplementary Fig. 2). Notably, well established α domain VHL mutants C162F
and L158S, which cannot form an ECV 40,43, likewise decreased pJAK2 levels (Fig. 2e).
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These results infer that a novel ECV-independent mechanism is responsible for VHL-
mediated pJAK2 degradation.
To begin addressing the autonomy of HIF and JAK2 functions of VHL, we asked what the
status of HIF and STAT5 responsive target genes were in microarray data available for RCC
and matched normal kidney samples 44. The vast majority of RCC harbour VHL inactivating
mutations, resulting in HIF stabilization. We have previously shown that the gene
expression changes induced by VHL inactivation are highly correlated with those induced
by HIF activation 24 and therefore hypothesized that RCCs would have high HIF-target gene
expression. Indeed relative to matched normal kidney, the RCCs expressed a classic hypoxic
signature including the upregulation of VEGF and CA9 and downregulation of IGFBP2 (Fig.
2f left panel). In contrast, the STAT5-responsive genes SOCS1, CISH and RYK showed no
discernable changes in RCC (Fig. 2f right panel), reinforcing the notion that the oncogenic
defects that give rise to RCC are unlikely to involve JAK2 signalling.
VHL binds to and requires SOCS1 to promote pJAK2 degradation
VHL, as well as certain F-box proteins that confer substrate specificity, have been shown
recently to homodimerize45–49. Moreover, homodimerization of entire E3 enzymes such as
the SCF (Skp1/Cdc53 or Cul1/F-box protein) have been shown to increase the efficiency of
ubiquitylation by improving spatial orientation of substrate to active site49. We asked
whether an F-box-like protein SOCS1 interacts with VHL to promote ECV-independent
degradation of pJAK2. T7-VHL co-precipitated HA-SOCS1 when ectopically expressed in
HEK293 cells (Fig. 3a, left panel), and similar results were obtained by reciprocal
immunoprecipitation (Fig. 3a, right panel). Co-expression of VHL with SOCS1, 2 and 3
revealed preferential interaction between VHL and SOCS1 (Fig. 3b), which is in keeping
with the known role of SOCS1, but not SOCS2 or 3, in the ubiquitin-mediated pJAK2
degradation 32,50. Notably, endogenous VHL co-precipitated endogenous SOCS1 in BaF3-
EPOR cells treated with EPO (Fig. 3c) and affinity-purified recombinant HA-VHL(C162F),
which cannot bind elongins B/C, Rbx1 and Cul2, bound specifically to re-natured FLAG-
SOCS1 resolved on membrane (Fig. 3d). These results suggest a direct interaction between
SOCS1 and VHL under physiologic conditions.
VHL(F119S) and VHL(L128F) mutants fail to promote pJAK2 degradation (Fig. 3e and see
Fig. 2f), but are capable of forming an intact ECV to properly target HIFα for degradation
(Fig. 3f), which further support the notion that the defect in pJAK2 regulation is independent
of ECV function. Both F119S and L128F mutants were, however, severely compromised in
binding SOCS1 (Fig. 3g) despite retaining the ability to bind JAK2 (data not shown),
underscoring the potential requirement of SOCS1, rather than ECV complex formation, in
VHL-mediated pJAK2 degradation. Moreover, analogous to the α domain of VHL, the
SOCS-box of SOCS1 facilitates the recruitment of the ECS components including Cul5,
Elongins BC and Rbx1 33,51,52. While both VHL(WT) and VHL(C162F; α domain mutant
that cannot form an ECV) mutant promoted pJAK2 degradation when co-expressed with
wild-type SOCS1, co-expression of SOCS1ΔSOCS-box mutant abrogated pJAK2
degradation (Fig. 3h). These results suggest that the SOCS-box is necessary for enzymatic
activity of the VHL/SOCS1 heterocomplex for the degradation of pJAK2.
CP-VHL has altered affinity for SOCS1, attenuating pJAK2 engagement
We asked whether the observed defect in pJAK2 degradation via CP-VHL was due to a
failure in binding SOCS1. Unexpectedly, both VHL(R200W and H191D) mutants showed a
dramatic increase in SOCS1 binding in comparison to their wild-type VHL counterpart (Fig.
4a), which suggests that CP-causing mutations confer significantly higher affinity for
SOCS1. We next asked whether this altered affinity of CP-VHL for SOCS1 affected pJAK2
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recruitment. pJAK2 co-precipitated significantly lower amounts of CP-VHL mutants in
comparison to VHL(WT), suggesting that the abnormal association between CP-VHL and
SOCS1 hinders pJAK2 substrate binding (Fig. 4b). We next directly compared the
efficiency of VHL(WT)/SOCS1 against CP-VHL/SOCS1 in promoting pJAK2 degradation.
T7-pJAK2 was first generated by ectopic expression of EPOR and T7-JAK2 in HEK293
cells followed by EPO stimulation. Cells were lysed and immunoprecipitated with an anti-
T7 antibody. T7-pJAK2 enriched on beads were washed and equally distributed into 4
reaction tubes, as confirmed by comparable levels of anti-T7 lgGL (Fig. 4c, bottom panel),
and mixed with HEK293 cell lysates expressing empty plasmid (Mock), HA-VHL(WT,
R200W or H191D) in combination with HA-SOCS1. VHL(WT)/SOCS1 containing lysate
markedly reduced the level of pJAK2 in comparison to CP-VHL/SOCS1 or SOCS1 only
containing lysates (Fig. 4c). Consistent with this observation, EPO-induced pJAK2 levels
persisted longer in BaF3-EPOR-shVHL cells reconstituted with lentivirus-mediated HA-
VHL(R200W) in comparison to HA-VHL(WT) reconstitution (Fig. 4d). These results
demonstrate that the CP-VHL/SOCS1 heterocomplex is defective in promoting pJAK2
degradation.
VHL negatively regulates EPOR-mediated JAK2-dependent colony growth
Stable knockdown of VHL in BaF3-EPOR cells increased the number of colonies in 1%
methylcellulose at sub-saturating EPO concentrations (Fig. 4e, top panel, 50 and 100mU). In
contrast, no significant changes were observed in colony number between VHL knockdown
and non-targeting control BaF3-EPOR cells in increasing IL3 concentrations (Fig. 4e,
bottom panel), which suggests a yet-defined complexity of regulation at the level of receptor
specificity. We asked whether the increased EPOR-specific colony formation upon VHL
loss involved JAK2. The molar concentration of highly specific JAK2 inhibitor (TG101209;
0.6μM) that resulted in a mild reduction in colony formation of BaF3-EPOR cells plated on
methylcellulose containing a sub-saturating EPO concentration was first determined
(Supplementary Fig. 3). At this concentration of TG101209, the percent inhibition of colony
formation was more pronounced in BaF3-EPOR with stable VHL knockdown than in non-
targeting control cells (Fig. 4f). In addition to a quantitative increase in colony number,
VHL loss increased the actual size of the colonies, which was reduced upon TG101209
treatment (Fig. 4g). These results suggest that VHL negatively regulates EPOR-mediated
colony growth and size in a JAK2-dependent manner.
JAK2 inhibitor treatment corrects CP phenotypes in vivo
VhlR/R mice harbouring a homozygous R200W mutation have been shown to develop age-
dependent polycythemia with significant elevations in Hct starting at 14–16 weeks of age 18.
We generated a cohort of VhlR/R mice, at least 20 weeks of age, and subjected them to
treatment with TG101209 (100mg/kg) or vehicle by twice daily oral gavage53. The Hct
levels of TG101209-treated VhlR/R mice steadily declined from baseline while the Hct of
vehicle-treated mice were relatively unchanged (mean Hct at 5 weeks of treatment: 35.4%
and 49.4% respectively, P < 0.05) (Fig. 5a). The Hct levels of TG101209-treated wild-type
mice declined as expected (mean Hct decreased from approximately 42% to 33% over 5
weeks). The difference in Hct was clearly evident by comparison of the plantar footpads of
the VhlR/R mice but not wild-type mice (Fig. 5b and Supplementary Fig. 4).
Splenomegaly is a common distinguishing feature of primary polycythemia and evident in
VhlR/R mice 18. At the time of necropsy, the spleens of vehicle-treated VhlR/R mice were
noticeably larger than those of TG101209-treated counterparts (Fig. 5c). In contrast, the
spleens of wild type mice treated with TG101209 or vehicle were indistinguishable
(Supplementary Fig. 4). Previous reports have shown that the spleens of VhlR/R mice have an
increased number of megakaryocytes, another feature of primary polycythemia not evident
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in secondary polycythemia 18. Evaluation of H&E stained sections of the spleens revealed a
significantly increased number of megakaryocytes in vehicle-treated VhlR/R mice relative to
TG101209-treated mice (Fig. 5c, arrows, and Fig. 5d, P < 0.005). These results suggest that
splenomegaly and the increased proliferation of megakaryocytes seen in VhlR/R mice are
JAK2-dependent.
We next asked to what extent our in vivo findings were mediated in a cell autonomous
manner. Erythroid progenitors from PV patients are hypersensitive to EPO due to JAK2
activating mutations associated with increased levels of phosphorylated JAK2 and
STAT5 39. Consistent with previous reports showing that erythroid progenitors from CP
patients and VhlR/R mice are hypersensitive to EPO 13,18, we observed an increased number
of CFU-E colonies in EPO-treated erythroid progenitors from VhlR/R mice compared to WT
mice (Fig. 5e). In order to determine whether the primary hypersensitivity was mediated in a
JAK2-dependent manner we first asked whether pJAK2 was upregulated in the erythroid
precursors of VhlR/R mice. To this end, single cell suspensions enriched with erythroid
progenitors were generated from spleens of phenylhydrazine-treated VhlR/R or WT mice and
residual cytokines were removed by washes in cytokine-free media. Cells were cytokine
starved for an additional 4 h to purge any pre-existing stimulation of the JAK2-STAT5
pathway and subsequently treated with increasing concentrations of exogenous EPO for 15
min. Expression levels of pJAK2 and pSTAT5 were markedly higher in VhlR/R compared to
the WT erythroid progenitor-enriched cell lysates (Fig. 5f), suggesting that their
hypersensitivity to EPO might be mediated in a JAK2-dependent manner. Moreover,
consistent with observations made in cell lines, VHL(R200W) isolated from VhlR/R splenic
cells co-precipitated endogenous SOCS1 and JAK2 (Fig. 5g).
To further ascertain whether the hypersensitivity of VhlR/R erythroid precursors to EPO was
mediated in a JAK2-dependent manner, we evaluated the effects of JAK2 inhibition by
performing CFU-E assays using haematopoietic precursors isolated from the spleens of
VhlR/R mice in the presence or absence of exogenous EPO and TG101309 or vehicle. No
CFU-E colonies were appreciable in the absence of EPO in either vehicle- or TG101209-
treated mice (data not shown). In the presence of EPO, the number of CFU-E formed was
significantly lower in haematopoietic precursors cultured in the presence of TG101209
relative to vehicle (Fig. 5h), suggesting that the hypersensitivity of VhlR/R haematopoietic
precursors to EPO is mediated in a JAK2 dependent-manner. These results demonstrate that
homozygous R200W mutation increases JAK2-STAT5 signalling and impart
hypersensitivity to EPO in a JAK2-dependent manner.
DISCUSSION
Mapping of VHL disease-associated mutations on VHL/Elongin B/Elongin C (VBC) crystal
structure engaged with HIF1α peptide has revealed two major domains α and β required for
Elongin C and HIF1α binding, respectively 7,8,54. VHL mutations that disrupt (F119S and
L128F) or enhance (R200W and H191D) SOCS1 binding interestingly clustered to a unique
third region of VHL, revealing a likely protein-protein interaction interface or ‘SOCS
groove’ required for the engagement of SOCS1 (Fig. 6a). Notably, the SOCS groove does
not overlap with Elongin C or HIF1α binding interface. This is consistent with the observed
autonomy of HIF- and JAK2- associated functions of VHL clearly revealed by F119S and
L128F mutants, which retain the ability to degrade HIFα but fail to degrade pJAK2 despite
their ability to form ECV. Conversely, α domain C162F mutant retains the ability to degrade
pJAK2 despite its inability to form ECV and degrade HIFα.
The present findings support the following revised model of CP (Fig. 6b). In normal
individuals, VHL forms a proper ECV complex and negatively regulate HIFα via the
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ubiquitin pathway. In contrast, CP-associated mutations attenuate HIFα binding and ECV
complex formation, causing the reported mild stabilization of HIFα, which leads to the
overproduction of HIF-target EPO in the kidney and secondary polycythemia. In normal
individuals, VHL also binds SOCS1 through its SOCS groove and trigger ubiquitin-
mediated pJAK2 degradation, and thus negatively regulate the JAK2-STAT5 pathway. CP-
associated mutations cause conformational change within the SOCS groove, leading to an
inordinately tight CP-VHL/SOCS1 association and impede pJAK2 recruitment and
degradation. Resulting pJAK2 stabilization promotes hyperactivation of the JAK2-STAT5
pathway in erythroid progenitors, causing hypersensitivity to EPO and primary
polycythemia.
PV-associated JAK2(V617F) mutation causes uncontrolled expansion of RBCs, but also
gives rise to pleomorphic and clustered megakaryocytes hypersensitive to thrombopoietin,
which, similar to EPO, signals through JAK2 via the thrombopoietin receptor35. Abnormal
megakaryocyte function is thought to be critical in thrombotic complications frequently
observed in PV patients 42. Strikingly, VhlR/R mice exhibit increased number of
megakaryocytes that cluster and CP patients, like PV patients, often present with thrombotic
complications 13,18. In contrast, secondary polycythemia associated with elevated serum
EPO does not give rise to megakaryocyte defects; an observation faithfully supported in
mice with constitutive overexpression of EPO that do not develop thrombotic complications
despite inordinately high RBC count 55. Moreover, some CP patients appear not to exhibit
elevated serum EPO levels 15,17,56. These observations suggest that the hyperactive JAK2-
STAT5 signalling, rather than the increased EPO production due to a mild defect in HIF
regulation, is the principal mechanism underlying thrombotic complications observed in CP
patients. Perhaps more importantly, the ability of pharmacologic JAK2 inhibition to
normalize the number of splenic megakaryocytes in VhlR/R mice suggests that not only will
JAK2 inhibition be useful to lower the Hct of CP patients but might also be able to lower the
rate of thrombotic complications.
The discovery of JAK2 mutations in PV patients has certainly expedited the clinical trials of
JAK2 inhibitors in the management of PV. However, despite clinical features shared
between PV and CP, including hypersensitivity to EPO and megakaryocyte defects
associated with thrombotic complications, JAK2 inhibitors have not been considered for CP
patients since the critical role of JAK2 in the pathogenesis of CP has not been, until now,
realized. Thus, the present findings not only uncover a molecular cooperativity between
VHL and SOCS1 in the negative regulation of JAK2-STAT5 pathway, but also provide
compelling biochemical and preclinical evidence for JAK2-targeted therapy in CP patients.
METHODS
Methods and any associated references are available in the online version of the paper at
http://www.nature.com/naturemedicine/.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. CP-VHL exhibits altered binding to ECV components and JAK2
(A) HEK293 cells transfected with the indicated plasmids were immunoprecipitated and
immunoblotted with the indicated antibodies. (B) 35S-radiolabelied 786-O subclones stably
expressing indicated HA-VHL were immunoprecipitated with anti-HA antibody, resolved
by SDS-PAGE and visualized by autoradiography. (C) HEK293 cells transfected with the
indicated combination of plasmids were treated with (+) or without (−) MG132. Equal
amounts of cell lysates were immunoprecipitated and immunoblotted with the indicated
antibodies. (D) HEK293 cells transfected with the indicated plasmids were lysed in the
absence of MG132, immunoprecipitated and immunoblotted with the indicated antibodies.
WCE: whole cell extract; IP: immunoprecipitation; IB: immunoblot; AR: autoradiography;
Asterisk: non-specific protein bands.
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Figure 2. VHL promotes ubiquitin-mediated destruction of pJAK2
(A) HEK293 cells transfected with the indicated plasmids were lysed and immunoblotted
with the indicated antibodies. (B) BaF3-EPOR cells infected with retrovirus encoding HA-
VHL were lysed, immunoprecipitated with anti-HA or isotype-matched control antibody and
immunoblotted with anti-VHL antibody (right panel). The same HA-VHL-expressing BaF3-
EPOR cells treated with (+) or without (−) EPO were immunoprecipitated and
immunoblotted with the indicated antibodies (left panel). (C) HEK293 cells transfected with
the indicated plasmids were treated with (+) or without (−) 20U ml−1 of EPO and pJAK2
isolated via anti-T7 immunoprecipitation (left panel), which was then added to an in vitro
ubiquitylation reaction containing proteasome-depleted S100 fractions with (+) or without
(−) VHL (right panels). Reaction mixtures were re- immunoprecipitated with anti-T7
antibody and immunoblotted with the indicated antibodies. (D) BaF3-EPOR-shVHL or -
shScr cells stimulated with EPO for indicated time periods were lysed and immunoblotted
with the indicated antibodies. RNA was also extracted and indicated STAT5- responsive
mRNA levels were measured by quantitative real-time PCR normalized to GAPDH and
EPO-stimulated levels of transcripts in BaF3-EPOR-shScr cells arbitrarily set to 1.0 (graph).
Error bars represent standard deviations of the fold-changes over three independent
experiments. (E) HEK293 cells transfected with indicated plasmids were lysed and
immunoblotted with the indicated antibodies. (F) Expression profiles of known HIF- (left
panel) and STAT5- (right panel) responsive genes were generated by analysis of 18 RCC
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samples in comparison to normal matched tissue control run on the Affymetrix Human
Genome U133B Array (GEO GDS507)44. Median expression is indicated by horizontal bar.
Error bars represent the standard deviation in the levels for each sample set. Asterisk denotes
non-specific protein bands.
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Figure 3. VHL binds to and cooperates with SOCS1 to negatively regulate pJAK2
(A,B) HEK293 cells transfected with the indicated plasmids were lysed, immunoprecipitated
and immunoblotted with the indicated antibodies. (C) BaF3-EPOR cells stimulated with (+)
or without (−) EPO were lysed, immunoprecipitated with anti-VHL or isotype-matched
control antibody and immunoblotted with the indicated antibodies. (D) Affinity-purified
HA-VHL(C162F) and cell lysates generated from HEK293 cells expressing FLAG-SOCS1
or HA-VHL(C162F) were resolved on SDS-PAGE and immunoblotted with anti-HA
antibody (lanes 1–3). HEK293 cells transfected with empty plamid (Mock) or plasmid
encoding FLAG-SOCS1 were lysed and immunoblotted with anti-FLAG antibody (lanes 4
and 5) or immunoprecipitated with anti-FLAG antibody and far-Western blotted (FB) with
purified recombinant HA-VHL(C162F) followed by anti-HA antibody (lanes 6 and 7). (E)
Whole cell extracts prepared from HEK293 cells transfected with the indicated plasmids
were immunoblotted with the indicated antibodies. (F) 786-O subclones stably expressing
the indicated HA-VHL were lysed and immunoblotted with indicated antibodies (right
panel) or immunoprecipitated with anti-HA antibody and immunoblotted with indicated
antibodies (left panel). (G) HEK293 cells transfected with the indicated plasmids in
combination with a plasmid encoding HA-SOCS1 were lysed, immunoprecipitated and
immunoblotted with anti-VHL antibody. (H) Whole cell extracts prepared from HEK293
cells transfected with the indicated plasmids and stimulated with EPO were immunoblotted
with the indicated antibodies. Asterisk: non-specific protein bands.
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Figure 4. CP-VHL mutants are defective in pJAK2 degradation and pharmacologic JAK2
inhibition attenuates VHL-dependent BaF3-EPOR colony formation
(A) HEK293 cells transfected with the indicated plasmids were lysed, immunoprecipitated
and immunoblotted with anti-HA antibody. (B) HEK293 cells transfected with the indicated
plasmids were treated with EPO and MG132, lysed, immunoprecipitated and immunoblotted
with the indicated antibodies. (C) Equal amounts of T7-pJAK2 isolated from EPO-treated
HEK293 cells were mixed with HEK293 cell lysates expressing indicated plasmids.
Reaction mixtures were immunoprecipitated with anti-T7 antibody and immunoblotted with
anti-pJAK2 antibody. (D) BaF3-EPOR-shVHL cells infected with lentivirus encoding HA-
VHL(R200W and WT) were treated with EPO for indicated time periods and
immunoblotted with the indicated antibodies. (E) Polyclonal BaF3-EPOR cells stably
expressing shVHL or shScr were plated in 1% methylcellulose containing the indicated
levels of EPO (top graph) or IL3 (bottom graph). Colony numbers were generated from a
single-blind analysis and are representative of four (top graph) or three (bottom graph)
independent experiments performed in duplicate. Error bars represent standard deviation
between replicate wells. (F) BaF3-EPOR cells were plated in 1% methylcellulose containing
EPO in combination with the indicated concentrations of JAK2 inhibitor TG101209. Colony
numbers were generated from a single-blind analysis and are representative of two
independent experiments performed in triplicate. Error bars represent standard deviation
between replicate wells. (G) BaF3-EPOR-shVHL and -shScr cells were plated in 1%
methylcellulose containing 100mU EPO in combination with the indicated concentrations of
TG101209. Eighty colonies were counted for each condition and average colony size was
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determined by digitization of microscope photographs followed by measurement of pixel
count for each colony, generating an arbitrary two-dimensional area directly proportional to
colony size. Scare bar = 0.2mm. Colonies extracted from methylcellulose were lysed and
immunoblotted with the indicated antibodies (right panels).
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Figure 5. TG101209 treatment rescues polycythemia features in VhlR/R mice
(A) Hct levels of vehicle or TG101209 treated VhlR/R mice. Normal Hct range highlighted in
grey. P < 0.05 after 5 weeks of treatment. Error bars = standard error of the mean (SEM).
(B) Photographs of the plantar footpads of vehicle and TG101209 treated VhlR/R mice. Scale
bar = 3.0mm (C) Photographs of spleens (scale bar = 4.0mm) and photomicrographs of
H&E stained sections of spleens (scale bars = 10μm) from VhlR/R mice treated with vehicle
or TG10209. Yellow arrows indicate megakaryocytes. (D) Quantification of average number
of megakaryocytes per high power field in spleens of vehicle or TG101209 treated VhlR/R
mice, P < 0.005. Error bars = SEM. (E) Numbers of CFU-E colonies formed from the
splenic haematopoietic precursors of VhlR/R versus WT mice when cultured in the presence
of 3U ml−1 of EPO, P < 0.005. Error bars = SEM. (F) Single cell suspensions enriched with
erythroid progenitors generated from spleens of phenylhydrazine-treated VhlR/R or WT mice
were washed, starved in cytokine-free media and treated with increasing concentrations of
exogenous EPO for 15 min. Cell lysates were then immunoblotted with the indicated
antibodies. (G) VhlR/R splenic cells were lysed and sonicated in the presence of phosphatase
inhibitors and MG132. Lysates were equally divided, immunoprecipitated with anti-VHL or
isotype-matched control antibody, and immunoblotted with the indicated antibodies. (H)
Numbers of CFU-E colonies formed from the splenic haematopoietic precursors of VhlR/R
Russell et al. Page 18
















mice when cultured in the presence of vehicle or TG101209, P < 0.05. Error bars = SEM.
Asterisk denotes non-specific protein bands.
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Figure 6. The ‘SOCS groove’ and the revised molecular model of CP
(A) Mutations that influence SOCS1 binding are clustered within the ‘SOCS-groove’ as
indicated (red) on the VHL/Elongin B/Elongin C crystal structure bound to HIF1α peptide.
Analyzed using DeppView/Swiss-PdbViewer v4.0. (B) Molecular model of CP. See text for
details.
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